# Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity

> **NCT01760642** · PHASE1 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Midazolam
- **DRUG:** Ketoconazole
- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT01760642
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01760642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01760642, "Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01760642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*